Hypertension, or high blood pressure, affects nearly half of Americans and is the most important risk factor for heart disease and stroke – the two leading causes of death in the world. Yet nearly 1 in 3 individuals with hypertension struggle to control their blood pressure despite being on medication.
If you’ve been unable to control your blood pressure even while taking multiple medications, it’s time to consider a new approach and see if you may be a candidate for the RADIANCE-HTN Clinical Study at Massachusetts General Hospital.
The RADIANCE-HTN Study is evaluating the Paradise® Renal Denervation System, a new approach which may lower your blood pressure and reduce your need for blood pressure medications.
People with high blood pressure typically have overactive renal (kidney) nerves, and it has been shown that calming these overactive nerves can help reduce blood pressure. The Paradise Renal Denervation System was designed to calm these overactive nerves through a one-time, minimally-invasive procedure.
A small catheter is placed in the artery supplying the kidney. Ultrasound energy (sound waves) is delivered for a few seconds to lower the over-activity of the nerves. After both kidneys are treated, the catheter is removed leaving nothing behind.
Hear patient and physician perspectives about the RADIANCE-HTN Study and need for an alternative approach to managing high blood pressure.
If you choose to join the study, you will receive all study-related care at no cost. This includes the procedure, as well as any follow-up visits to your study doctor’s office. You will also be reimbursed for your time and travel to attend these study visits.
The Paradise® Renal Denervation System may lower your blood pressure and reduce your need for blood pressure medications. Participants in the RADIANCE-HTN Study may also benefit from:
As with all clinical studies, your participation is completely voluntary, and you may leave the study at any time without any effect on your future medical care.